Protein arginine methyltransferases and hepatocellular carcinoma: A review

• Main Authors: Yu Lei, Ping Han, Dean Tian
• Format: Article
• Language: English
• Published: Elsevier 2021-11-01
• Series: Translational Oncology
• Subjects: Protein arginine methyltransferases; Hepatocellular carcinoma; Therapeutic; Inhibitors
• Online Access: http://www.sciencedirect.com/science/article/pii/S1936523321001868

Hepatocellular carcinoma (HCC) is one of the most frequently diagnosed cancers with a high mortality rate worldwide. The complexity of HCC initiation and progression poses a great challenge to the diagnosis and treatment. An increasing number of studies have focused on the emerging roles of protein arginine methylation in cancers, including tumor growth, invasion, metastasis, metabolism, immune responses, chemotherapy sensitivity, etc. The family of protein arginine methyltransferases (PRMTs) is the most important proteins that mediate arginine methylation. The deregulation of PRMTs’ expression and functions in cancers have been gradually unveiled, and many PRMTs inhibitors are in preclinical and clinical investigations now. This review focuses predominantly on the aberrant expression of PRMTs, underlying mechanisms, as well as their potential applications in HCC, and provide novel insights into HCC therapy.